Medsential Offering an FDA EUA Approved COVID Point of Care Antibody Rapid Test

December 23, 2020

Medsential has announced that it is now offering COVID-19 IgM/IgG rapid antibody tests to point of care providers and is able to meet high demand. The test has recently received FDA emergency use authorization.

“We are thrilled to have a point of care rapid antibody test now available. We know hospitals, medical offices, and other point of care providers have been eager to make these available to their patients to provide peace of mind,” said Doris Hui, CEO of Medsential.

“Medsential’s testing technology is what our BioHive ‘buzz’ is all about,” said Kelvyn Cullimore, president and CEO of BioUtah. “This company, with offices in Salt Lake City, is innovating to respond to COVID-19 and help patients. They’re one of many success stories that is putting Utah’s life sciences industry on the map.”

“Our rapid test kits show three levels of antibody build-up, unlike many other antibody tests that show only one,” said Hui. “This allows for more accurate identification of community spread and exposure to coronavirus. Health care providers can assess the exposure of their staff and their patients to better protect vulnerable populations, including detecting COVID-19 before symptoms occur. In addition, our test can identify immunity to the virus as our bodies build up antibodies.”

Medsential has manufacturing and distribution operations in the U.S., China, and Japan and will be able to meet high-volume demand for these antibody tests.